C.R. Bard, Inc. (NYSE:BCR) Stake Reduced by Sheets Smith Wealth Management
Sheets Smith Wealth Management lowered its position in C.R. Bard, Inc. (NYSE:BCR) by 4.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 3,533 shares of the medical instruments supplier’s stock after selling 162 shares during the period. Sheets Smith Wealth Management’s holdings in C.R. Bard were worth $1,117,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the company. Pennsylvania Trust Co boosted its position in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock worth $308,000 after buying an additional 35 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of C.R. Bard by 1.0% in the first quarter. Gulf International Bank UK Ltd now owns 23,124 shares of the medical instruments supplier’s stock valued at $5,747,000 after buying an additional 220 shares during the period. Trust Co. of Oklahoma boosted its position in shares of C.R. Bard by 1.0% in the first quarter. Trust Co. of Oklahoma now owns 9,700 shares of the medical instruments supplier’s stock valued at $2,411,000 after buying an additional 100 shares during the period. Creative Planning boosted its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the period. Finally, Contravisory Investment Management Inc. boosted its position in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the period. Institutional investors and hedge funds own 86.21% of the company’s stock.
Get C.R. Bard Inc. alerts:
C.R. Bard, Inc. (NYSE:BCR) traded up 0.07% on Monday, hitting $320.60. 519,937 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $317.56 and a 200-day moving average price of $277.60. The stock has a market cap of $23.30 billion, a P/E ratio of 42.09 and a beta of 0.59. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $323.27.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a return on equity of 49.89% and a net margin of 14.99%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.54 earnings per share. Analysts predict that C.R. Bard, Inc. will post $11.78 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be paid a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.32%. C.R. Bard’s dividend payout ratio is currently 13.67%.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/07/31/sheets-smith-wealth-management-cuts-position-in-c-r-bard-inc-nysebcr-updated.html.
BCR has been the subject of several recent research reports. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price target for the company in a research report on Thursday, May 11th. BMO Capital Markets reaffirmed a “buy” rating and issued a $255.00 price objective on shares of C.R. Bard in a research note on Tuesday, April 11th. Raymond James Financial, Inc. lowered shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Wells Fargo & Company lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. Finally, Cowen and Company upped their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. C.R. Bard has a consensus rating of “Hold” and a consensus price target of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
What are top analysts saying about C.R. Bard Inc.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.